Roche Holding AG (RO.S)
Mon, Aug 20 2018
ZURICH Roche's Alecensa lung cancer medicine became the latest beneficiary of China's efforts to speed up approvals in the world's second-biggest drug market, which is gaining importance for global pharmaceuticals companies' growth plans.
ZURICH, Aug 20 Chinese regulators are speeding up drug approvals, with Roche's Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies' growth plans.
* HEALTH CANADA APPROVES HEMLIBRA® FOR HEMOPHILIA A PATIENTS WITH INHIBITORS Source text for Eikon: Further company coverage:
ZURICH Roche on Thursday lifted its veil of secrecy over a patent that has reaped billions of dollars over the years but is due to expire on Dec. 18, depriving the Swiss drugmaker of a key source of income.
ZURICH, July 26 Roche on Thursday lifted its veil of secrecy over a patent that has reaped billions of dollars over the years but is due to expire on Dec. 18, depriving the Swiss drugmaker of a key source of income.
ZURICH Swiss drugmaker Roche on Thursday outshone crosstown rival Novartis by boosting its 2018 sales outlook, helped by new medicines in a year when many feared patent expirations and cheaper copies would put growth at risk.
* Shares rise 3 percent (Adds comment from CEO, analyst, details about rivals)
ZURICH, July 26 Swiss drugmaker Roche lifted its 2018 outlook on Thursday for the second time this year, after first-half sales and profit easily beat analyst expectations on the strength of newer drugs including multiple sclerosis treatment Ocrevus.
* PURETECH HEALTH ANNOUNCES COLLABORATION WITH ROCHE TO ADVANCE TECHNOLOGY FOR ORAL ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES
ZURICH The U.S. Food and Drug Administration has granted Roche an accelerated review for its Elecsys product used to diagnose Alzheimer's disease, the Swiss drugmaker said on Friday.